ADC Therapeutics SA
ADCT
$3.54
-$0.41-10.38%
NYSE
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -12.80% | -18.21% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -12.80% | -18.21% | |||
| Cost of Revenue | -9.45% | 1,400.53% | |||
| Gross Profit | 4.21% | -157.63% | |||
| SG&A Expenses | 0.24% | -7.50% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.76% | -3.11% | |||
| Operating Income | 1.49% | -9.11% | |||
| Income Before Tax | 26.04% | -44.11% | |||
| Income Tax Expenses | -- | 660.00% | |||
| Earnings from Continuing Operations | 27.68% | -46.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 27.68% | -46.74% | |||
| EBIT | 1.49% | -9.11% | |||
| EBITDA | 0.34% | -9.15% | |||
| EPS Basic | 39.72% | -38.29% | |||
| Normalized Basic EPS | 20.01% | -3.70% | |||
| EPS Diluted | 39.72% | -38.29% | |||
| Normalized Diluted EPS | 20.01% | -3.70% | |||
| Average Basic Shares Outstanding | 19.96% | 6.10% | |||
| Average Diluted Shares Outstanding | 19.96% | 6.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||